Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24698421 | 0.81 | TDP2 (0.39) | KDM1ABACE1 | |
| SCHEMBL3465090 | 0.81 | PDE7A (0.53) | ADRA2ACYP2C19PDE7AKDM1AAR | |
| SCHEMBL7823957 | 0.80 | ADRA2A (0.54) | ADRA2APDE7APRNPARSMN1; SMN2 | |
| SCHEMBL7828016 | 0.80 | ADRA2A (0.54) | ADRA2APDE7APRNPSMN1; SMN2BACE1 | |
| SCHEMBL743696 | 0.80 | CYP2C19 (0.35) | ADRA2ACYP2C19PDE7AKDM1AAR | |
| SCHEMBL742364 | 0.77 | TSHR (0.48) | KDM1AALDH1A1 | |
| SCHEMBL742411 | 0.71 | KDM1A (0.42) | ADRA2ACYP2C19KDM1AARBACE1 | |
| SCHEMBL742452 | 0.71 | KDM1A (0.39) | ADRA2ACYP2C19KDM1AAR | |
| SCHEMBL1972093 | 0.71 | TSHR (0.58) | PDE7A | |
| SCHEMBL28465895 | 0.70 | KDM1A (0.48) | ADRA2ACYP2C19PDE7AKDM1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010540-B1 | SPIRO-IMIDAZO COMPOUNDS | NOVARTIS AG (CH) | 2012-12-05 | — | — | EP | disclosed |
| US-8138179-B2 | Spiro-imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-8138179-B2 | Spiro-imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-20090192145-A1 | Spiro-Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192145-A1 | Spiro-Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2007116098-A1 | SPIRO-IMIDAZO COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192145-A1 | Spiro-Imidazo Compounds | REN, NR3C2, AGTR1 | ADRA2A 138/4885CYP2C19 89/4885PDE7A 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.